<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482272</url>
  </required_header>
  <id_info>
    <org_study_id>ENTADE</org_study_id>
    <nct_id>NCT02482272</nct_id>
  </id_info>
  <brief_title>Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B</brief_title>
  <official_title>Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare efficacy and safety of continuing Lamivudine plus
      Adefovir or Adefovir versus switching to Entecavir plus Adefovir in patients with
      LAM-resistant chronic hepatitis B who have suboptimal response to Lamivudine plus Adefovir or
      Adefovir
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HBV DNA&lt;15IU/mL</measure>
    <time_frame>week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBV DNA&lt;15IU/mL</measure>
    <time_frame>Day1, week12, week 24, week 36, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HBV DNA from the baseline</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ALT normalization</measure>
    <time_frame>Day1, week12, week 24, week 36, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBeAg loss and/or seroconversion</measure>
    <time_frame>Day1, week12, week 24, week 36, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HBsAg from the baseline</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBsAg loss and/or seroconversion</measure>
    <time_frame>week 24, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who experienced virologic breakthrough</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment the safety in all patients (composite measure of AE, labs, phys. exam, vital signs)</measure>
    <time_frame>week 48</time_frame>
    <description>Composite outcome measure consisting of multiple measures, including:
Number of patients with Adverse events( including SAEs)
Frequency and severity of Abnormalities in laboratory examinations; BUN, Albumin, AST, ALT,GGT, Creatinine, Hemoglobin, Hematocrit, Platelet Count, Prothrombin time
Number of patients with Abnormalities in physical examinations; Eyes/Ears/Nose/Throat, Respiratory, Cardiovascular, Dermatological, Abdominal, Musculoskeletal, Other
Number of patients with Abnormalities in vital signs ; pulse rate( beats per minute), Blood pressure(mmHg), Height(cm), weight(kg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Lamivudine plus Adefovir or Adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamivudine+Adefovir or Adefovir for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir plus Adefovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir+Adefovir for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine 100mg/day orally</description>
    <arm_group_label>Lamivudine plus Adefovir or Adefovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
    <description>Adefovir 10mg/day orally</description>
    <arm_group_label>Lamivudine plus Adefovir or Adefovir</arm_group_label>
    <arm_group_label>Entecavir plus Adefovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 1mg/day orally</description>
    <arm_group_label>Entecavir plus Adefovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B

          -  Age ≥ 20 year old

          -  Currently taking Lamivudine and Adefovir combination therapy or Adefovir monotherapy
             for chronic HBV infection for 24 weeks

          -  Proven Lamivudine resistant mutation

          -  HBV DNA levels at screening ≥ 15 IU/mL

          -  Females must be post-menopausal, unable to conceive, or test negative for pregnancy
             via urine test

          -  Patient is able to give written informed consent prior to study start and to comply
             with the study requirements

        Exclusion Criteria:

          -  A history or current of decompensated cirrhosis or hepatocellular carcinoma

          -  Currently receiving antiviral, immunomodulatory, cytotoxic or corticosteroid therapy

          -  Co-infected with HCV or HIV

          -  A history of organ transplantation

          -  Pregnant or breast-feeding

          -  Current clinically relevant of abuse of alcohol or drugs.

          -  Significant immunocompromised, gastrointestinal, renal(serum creatinine ≥ 1.5 mg/dL),
             hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic
             GB stone, neurological, cardiac, oncologic, allergic disease or medical illness that
             in the investigator's opinion might interfere with therapy

          -  malignancy in previous 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danbi Lee</last_name>
    <phone>82)2-3010-3907</phone>
    <email>leighdb@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Hwa Chung</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Hwa Chung</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

